Su1849: LONG-TERM OUTCOMES OF EXTENDED VERSUS CONVENTIONAL ADALIMUMAB DOSE INTERVAL FOR PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: 3-YEAR FOLLOW-UP OF THE RANDOMIZED CONTROLLED LADI TRIALLisa M. van Lierop, Frank Hoentjen, Nathan den Broeder et al.|Gastroenterology|2025Cited by 0